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INTRODUCTION
Sentinel lymph node biopsy (SLNB) is a standard proce-
dure in patients with breast cancer who have clinically nega-
tive lymph nodes. In comparison with initial axillary lymph 
node dissection (ALND), performing SLNB confers no sig-
nificant differences in either disease-free survival (DFS) or 
overall survival (OS) [1-3]. However, ALND is performed 
when axillary lymph node metastasis is confirmed via SLNB. 
Compared with ALND, SLNB requires less time and a smaller 
operating field, and SLNB has fewer side effects (e.g., seroma, 
hematoma, pain, and lymphedema). Potential adverse effects 
of ALND can considerably worsen the quality of life of the pa-
tient [1-4]. 
After the introduction of SLNB, there were some sugges-
tions made about omitting ALND in some patients with posi-
tive SLNB results, as there was no difference in survival in 
early breast cancer regardless of the axillary surgery method 
[5-7]. However, the major limitation in these reports is that 
they were small, single-institutional studies. The American 
College of Surgeons Oncology Group (ACOSOG) Z0011 trial 
randomized patients with early breast cancer who had posi-
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Purpose: Sentinel lymph node biopsy (SLNB) is a standard axil-
lary surgery in early breast cancer. If the SLNB result is positive, 
subsequent axillary lymph node dissection (ALND) is a routine 
procedure. In 2011, the American College of Surgeons Oncology 
Group Z0011 trial revealed that ALND may not be necessary in 
early breast cancer with one or two positive sentinel lymph 
nodes. The purpose of this study was to compare outcomes 
among Korean patients with one or two positive axillary lymph 
nodes in the final pathology who did and did not undergo ALND. 
Methods: A total of 131,717 patients from the Korea Breast Cancer 
Society registry database received breast cancer surgery from 
January 1995 to December 2014. Inclusion criteria were T stage 
1 or 2, one or two positive lymph nodes, and having received 
breast-conserving surgery (BCS), whole breast radiation therapy, 
and no neoadjuvant therapy. We analyzed the differences in 
disease-specific survival (DSS) and overall survival (OS) between 
patients who received SLNB only and those who underwent 
SLNB+ALND. Results: A total 4,442 patients met the inclusion 
criteria, with 1,268 (28.6%) in the SLNB group and 3,174 (71.4%) 
in the SLNB+ALND group. There were no differences in DSS 
and OS between the two groups (p=0.378 and p=0.925, re-
spectively). The number of patients who underwent SLNB alone 
for one or two positive lymph nodes increased continuously from 
2004 to 2014. Conclusion: Korean patients with early breast can-
cer and 1 or 2 positive axillary lymph nodes who received BCS 
plus SLNB showed no significant difference in DSS and OS re-
gardless of whether they received ALND. The findings of this ret-
rospective study demonstrate that omitting ALND can be con-
sidered when treating selected patients with early breast cancer 
who have one or two positive lymph nodes.
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tive SLNB results into groups undergoing SLNB alone and 
SLNB+ALND; no difference was found in patient survival 
rates [8]. In a follow-up study in 2016, disease-specific surviv-
al (DSS), OS, and local recurrence rates were also similar be-
tween the groups, and there were no significant differences in 
the 10-year DFS and regional recurrence between the two 
groups [9,10].
Based on these results, we used data from the Korean Breast 
Cancer Registry to investigate DSS and OS rates in patients 
with early breast cancer, who had one or two positive axillary 
lymph nodes in the final pathology and who did or did not 
undergo ALND. Furthermore, we investigated the annual 
number and proportion of patients undergoing breast-con-
serving surgery (BCS), with SLNB or SLNB+ALND, among 
patients with one or two positive axillary lymph nodes. Our 
overall goal was to provide results that would be useful for fu-
ture axillary surgeries in Korea. 
METHODS
Study population
The data in the Korean Breast Cancer Registry were collected 
by the Korean Breast Cancer Society (KBCS) from 41 university 
hospitals and 61 training hospitals in Korea. In the present 
study, we used data for the cause and date of death from this 
database in connection with the Central Cancer Registry 
data of the Ministry of Health and Welfare in cooperation 
with the Korean National Statistical Office, to compile com-
plete death statistics updated through 2014. This study was 
approved by Catholic Medical Center Daejeon St. Mary’s 
Hospital Institutional Review Board (No. DC17RISE0006) 
and waived the requirement for obtaining informed consent. 
Study design 
The study included 131,717 patients diagnosed with breast 
cancer, who were registered in the KBCS database from 1995 
to 2014. The following information was retrieved from the da-
tabase: age; sex; menopausal status; date of surgery; method of 
breast surgery; method of axillary surgery; tumor size at the 
time of diagnosis; presence and number of lymph metastases; 
histological type; estrogen receptor (ER), progesterone recep-
tor (PR), and human epidermal growth factor receptor 2 
(HER2) status; use of chemotherapy, radiotherapy, hormone 
therapy, and targeted therapy; and mortality status. We cate-
gorized molecular subtypes as follows: luminal A-like means 
ER and/or PR positive and HER2 negative; luminal B-like 
means ER and/or PR positive and HER2 positive; triple-nega-
tive means ER and PR negative and HER2 negative; HER2-
enriched means ER and PR negative and HER2 positive.
The inclusion criteria were as follows: (1) tumor stage 1 or 2 
(tumor size ≤ 5 cm); (2) clinically negative axillary lymph node 
metastasis; (3) one or two positive axillary lymph nodes in the 
final pathology; (4) BCS; and (5) whole breast radiation thera-
py. Ultimately, 4,442 patients in the KBCS database satisfied 
these criteria. The 4,442 patients were divided into two groups: 
those who received SLNB (SLNB group) and those who re-
ceived ALND after SLNB (SLNB+ALND group) (Figure 1). 
The primary endpoint of this study was to determine 
whether there is any significant difference in DSS and OS be-
tween patients who underwent SLNB and those who under-
went SLNB+ALND. The secondary endpoint was to describe 
the independent factors influencing DSS and OS.
 
Statistical analysis
The Student t-test was used to compare variables between 
the SLNB and SLNB+ALND groups. Intergroup comparisons 
of DSS and OS were verified via log-rank test, and prognostic 
131,717 Total breast 
cancer patients
66,043 Breast- 
conserving surgery
Axillary operation
10,007 SLNB+ALND
3,174 SLNB+ALND
27,469 SLNB only
1,268 SLNB only
Inclusion criteria
T-stage 1 of 2 (tumor size ≤5 cm)
Metastatic lymph node 1 or 2
C linically negative axillary lymph node 
metastasis
Breast-conserving surgery
Whole breast radiation therapy
28,567 ALND
Exclusion
6 5,674 Mastectomy, 
paiilative surgery 
Figure 1. Selection and categorization of patients with one or two posi-
tive axillary lymph nodes in the study cohort.
SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissec-
tion.
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indicators were identified using Cox regression analysis. Sur-
vival rates were determined from the date of diagnosis to the 
date of death due to breast cancer or any cause. The Student t-
test was used to compare variables between the SLNB and 
SLNB+ALND groups. Intergroup comparisons of DSS and 
OS were verified via log-rank test, and prognostic indicators 
were identified using Cox regression analysis. Statistical analy-
sis was performed using SAS version 9.3 (SAS Institute, Cary, 
USA), with a p-value < 0.05 as the threshold for statistical sig-
nificance.
RESULTS
Clinical characteristics
Among the 131,717 patients in the full dataset, 4,442 met 
the inclusion criteria, with 1,268 in the SLNB group (28.6%) 
and 3,174 in the SLNB+ALND group (71.4%). The clinical 
characteristics of the two groups are summarized in Table 1. 
The two groups differed in the number of positive lymph 
nodes (1.14± 0.34 vs. 1.30± 0.46, p< 0.001), total number of 
lymph nodes removed (5.90± 5.29 vs. 15.21± 7.08, p< 0.001), 
pathological stage (p< 0.001), molecular subtype (p= 0.016), 
and use of chemotherapy (p< 0.001). 
Survival outcomes
There were no significant differences in either DSS (p =  
0.378), or OS between the two groups (p= 0.925) (Figure 2). 
The mean follow-up period for the SLNB and SLNB+ ALND 
groups was 30.86± 25.21 months and 47.24± 30.56 months, 
respectively.
Factors associated with prognosis
In the univariate analysis, total lymph node count correlated 
significantly with DSS; OS was correlated with tumor size, 
positive lymph node status, histologic grade, lymphatic inva-
sion, vascular invasion, molecular subtype, and hormone 
therapy. In the multivariate analysis, histologic type correlated 
significantly with DSS; tumor size and positive lymph node 
status had a correlation with OS. The results for all variables 
are summarized in Tables 2 and 3.
Subgroup analysis according to molecular subtype
The relationship between the method of axillary surgery, 
and DSS and OS was assessed in the 4,442 patients. Study par-
ticipants were categorized into the following subgroups: lumi-
nal A-like subtype (n= 950), lumi nal B-like subtype (n= 58), 
triple-negative (n= 215), and HER2-enriched (n= 5). There 
was no significant association between method of surgery and 
survival in any of the subgroups (Figure 3). 
Table 1. Clinical characteristics of patients with early breast cancer, with 
one or two lymph node metastases via SLNB versus SLNB+ALND
Variable
SLNB only 
(n=1,268) 
No. (%)
SLNB+ALND 
(n=3,174) 
No. (%)
p-value
Age (yr)* 49.55±9.29 49.26±9.54 0.363
Tumor size (cm)* 1.81±0.84 1.88±0.84 0.008
No. of positive lymph nodes* 1.14±0.34 1.30±0.46 <0.001
No. of total excised lymph nodes* 5.90±5.29 15.21±7.08 <0.001
Stage <0.001
   I 220 (17.4) 83 (2.6)
   II 1,033 (81.5) 3,061 (96.4)
   III 7 (0.6) 10 (0.3)
   IV 0 4 (0.1)
   Unknown 8 (0.6) 16 (0.5)
Family history 0.238
   Yes 119 (9.4) 263 (8.3)
   No 1,149 (90.6) 2,911 (91.7)
Histologic grade† 0.882
   1 191 (15.6) 495 (16.2)
   2 652 (53.1) 1,628 (53.3)
   3 384 (31.3) 934 (30.6)
Histologic type† 0.144
   Invasive ductal 1,205 (95.7) 3,058 (96.9)
   Invasive lobular 44 (3.5) 74 (2.3)
   Others 10 (0.8) 25 (0.8)
Lymphatic invasion† 0.930
   Positive 490 (40.7) 1,237 (40.8)
   Negative 715 (59.3) 1,794 (59.2)
Vascular invasion† 0.557
   Positive 270 (24.3) 639 (23.4)
   Negative 843 (75.7) 2,095 (76.6)
EIC† 0.096
   Positive 194 (19.6) 560 (22.2)
   Negative 796 (80.4) 1,967 (77.8)
Molecular subtype† 0.016
   Luminal A-like 950 (77.4) 2,279 (73.1)
   Luminal B-like 58 (4.7) 166 (5.3)
   TNBC 215 (17.5) 639 (20.5)
   HER2-enriched 5 (0.4) 33 (1.1)
Chemotherapy† <0.001
   Yes 1,084 (85.7) 2,997 (94.5)
   No 181 (14.3) 174 (5.5)
Hormone therapy 0.165
   Yes 1,029 (81.2) 2,517 (79.3)
   No 239 (18.9) 657 (20.7)
Menopause† 0.200
   Yes   590 (46.7) 1,409 (44.6)
   No 673 (53.3) 1,751 (55.4)
SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; 
EIC=extensive intraductal component; TNBC=triple-negative breast cancer; 
HER2=human epidermal growth factor receptor 2.
*Mean±SD; †Number differences reflect missing data.
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Annual incidence of SLNB alone or SLNB+ALND in patients 
with one or two positive axillary lymph nodes
The number of patients who underwent SLNB alone for 
one or two positive lymph nodes has increased gradually since 
2004. The proportion of patients who underwent SLNB alone 
for one or two positive lymph nodes increased continuously 
from 2005 to 2014 (Figure 4).
Figure 2. Survival outcomes by sentinel lymph node biopsy (SLNB) versus SLNB+axillary lymph node dissection (ALND) in early breast cancer. (A) 
Disease-specific survival. (B) Overall survival. 
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Table 2. Univariate analysis of disease-specific and overall survival 
Variable
Disease-specific survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Age (yr)* 1.03 (0.97−1.10) 0.368 0.99 (0.98−1.02) 0.697
Axilla operation (SLNB vs. SLNB+ALND) 2.46 (0.31−19.55) 0.394 0.98 (0.61−1.58) 0.925
Family history (no vs. yes) 2.81 (0.60−13.25) 0.191 1.01 (1.01−0.51) 0.979
Size (cm)* 1.41 (0.71−2.79) 0.327 1.86 (1.53−2.26) <0.001
No. of positive nodes (1 vs. 2) 3.02 (0.88−10.44) 0.080 1.71 (1.71−1.15) 0.008
No. of total excised nodes* 1.10 (1.04−1.17) 0.002 1.01 (0.99−1.04) 0.318
Histologic grade 0.340 <0.001
   1 Reference Reference
   2 0.47 (0.08−2.80) 0.405 1.81 (0.76−4.32) 0.181
   3 1.36 (0.26−7.03) 0.711 6.05 (2.61−13.98) <0.001
Histologic type 0.711 1.00
   Invasive ductal carcinoma Reference Reference
   Invasive lobular carcinoma 4.66 (0.59−36.83) 0.144 0.85 (0.21−3.46) 0.824
Lymphatic invasion (negative vs. positive) 0.22 (0.03−1.74) 0.151 1.81 (1.22−2.67) 0.003
Vascular invasion (negative vs. positive) 0.44 (0.06−3.49) 0.435 1.90 (1.25−2.89) 0.003
EIC (negative vs. positive) 2.85 (0.77−10.62) 0.119 0.83 (0.49−1.41) 0.499
Molecular subtype 0.875 <0.001
   Luminal A-like Reference Reference
   Luminal B-like N.A† - 1.71 (0.80−3.64) 0.168
   TNBC 1.80 (0.45−7.21) 0.405 4.46 (2.95−6.72) <0.001
   HER2-enriched N.A† - 2.22 (0.54−9.25) 0.272
Hormone therapy (no vs. yes) 0.59 (0.15−2.27) 0.440 0.24 (0.16−0.35) <0.001
Menopause (no vs. yes) 3.08 (0.80−11.93) 0.103 1.01 (0.69−1.48) 0.956
HR=hazard ratio; CI=confidence interval; SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; EIC=extensive intraductal component; 
N.A=not applicable; TNBC=triple-negative breast cancer; HER2=human epidermal growth factor receptor 2.
*Age, size, and number of total excised nodes were assessed as continuous variables; †Can not calculate Hazard ratio because there is no occurrence of breast 
cancer related death.
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Figure 3. Disease-specific survival and overall survival according to molecular subtype. (A) Luminal A-like. (B) Luminal B-like. (C) Triple-negative. (D) 
HER2-enriched.
SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; HER2=human epidermal growth factor receptor 2. *Luminal B-like and 
HER2-enriched type has no disease-related death.
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DISCUSSION
Sentinel node biopsy could decrease morbidity in early 
breast cancer, and a previous study has shown that arm edema 
after axillary surgery occurs less frequently in patients who un-
dergo mastectomy and do not undergo ALND than in patients 
who undergo ALND [11]. Previous studies have suggested that 
axillary recurrence is rare in early breast cancer; thus, SLNB 
Table 3. Multivariate analysis of disease-specific and overall survival
Variable
Disease-specific survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Age (yr)*   0.96 (0.84−1.10) 0.588 0.99 (0.95−1.02) 0.463
Family history (no vs. yes)   4.23 (0.81−22.12) 0.088 0.87 (0.38−2.02) 0.743
Size (cm)*   1.22 (0.47−3.15) 0.679 1.58 (1.22−2.03) 0.001
No. of positive nodes (1 vs. 2)   1.36 (0.30−6.16) 0.688 1.81 (1.14−2.94) 0.013
No. of total excised nodes*   1.08 (0.99−1.16) 0.069 1.01 (0.98−1.04) 0.634
Histologic grade 0.973 0.412
   1 Reference Reference
   2   0.66 (0.06−7.87) 0.743 1.52 (0.52−4.42) 0.446
   3   4.21 (0.34−51.98) 0.262 2.60 (0.87−7.80) 0.087
Histologic type 0.999 0.807
   Invasive ductal carcinoma Reference Reference
   Invasive lobular carcinoma 31.32 (2.56−382.80) 0.007 1.69 (0.23−12.52) 0.605
Lymphatic invasion (negative vs. positive)   0.18 (0.01−3.40) 0.255 1.74 (0.91−3.33) 0.093
Vascular invasion (negative vs. positive)   1.72 (0.09−33.35) 0.722 0.93 (0.47−1.85) 0.829
EIC (negative vs. positive)   3.69 (0.78−17.49) 0.100 1.02 (1.58−1.80) 0.945
Molecular subtype 0.999 0.313
   Luminal A-like Reference Reference
   Luminal B-like N.A† - 1.16 (0.45−3.01) 0.755
   TNBC   0.63 (0.03−12.77) 0.760 1.81 (0.71−4.61) 0.211
   HER2-enriched N.A† - 1.32 (0.26−6.60) 0.739
Hormone therapy (no vs. yes)   0.69 (0.04−13.75) 0.810 0.46 (0.19−1.13) 0.091
Menopause (no vs. yes)   9.43 (0.68−130.89) 0.095 1.39 (0.68−2.88) 0.368
HR=hazard ratio; CI=confidence interval; EIC=extensive intraductal component; N.A=not applicable; TNBC=triple-negative breast cancer; HER2=human epi-
dermal growth factor receptor 2.
*Age, size and number of total excised nodes were assessed as continuous variables; †Can not calculate Hazard ratio because there is no occurrence of breast 
cancer related death.
Figure 4. Annual incidence of sentinel lymph node biopsy (SLNB) versus SLNB+axillary lymph node dissection (ALND) in patients with one or two 
positive axillary lymph nodes.
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without ALND may control axillary recurrence in selected pa-
tients [6,7]. Moreover, in patients with one to two positive 
lymph nodes on SLNB, DSS is not affected even when ALND 
is not performed [8,9,12,13]. Therefore, omitting ALND can 
be helpful to patients if there is no benefit for survival.
Some studies have shown that performing SLNB under cer-
tain conditions may not affect survival [5-7]. To validate pre-
vious studies using a different approach, we retrospectively 
analyzed the study groups who underwent SLNB or SLNB+ 
ALND. We included patients with only one or two positive 
lymph nodes in the final pathology, regardless of the type of 
axillary surgery. We excluded patients who were found to 
have further nodal metastases on subsequent ALND and were 
upgraded to N2/3 disease. This differed from the inclusion 
criteria in the ACOSOG Z0011 trial, in which 27.3% of par-
ticipants underwent ALND and had additional metastases in 
the excised lymph nodes; such patients may have worse prog-
nosis. At a median follow-up of 6.3 years in the ACOSOG 
study, 5-year OS was 92.5% with SLNB and 91.8% with 
SLNB+ALND [13]. In our study, with a mean of 47 months’ 
follow-up, OS was 98.3% in the SLNB group and 97.3% in the 
SLNB+ALND group. Despite several differences in study de-
sign, the present study showed no significant difference in OS 
regardless of the method of axillary surgery, in patients with 
early breast cancer and one or two positive axillary lymph 
nodes who received BCS.
In a randomized trial conducted in 2010, the decision to 
perform ALND after SLNB during BCS was made based on 
the size of the tumor and the number of metastatic lymph 
nodes [8]. Since then, several studies have been published in 
which ALND was not performed in patients with early breast 
cancer who had one to two positive lymph nodes on SLNB, 
with no adverse effects on DSS rates; the subsequent use of 
ALND tended to decrease over time [14-19]. In an analysis of 
Surveillance, Epidemiology, and End Results Program data, 
no differences were found in DSS or OS in patients with 
breast cancer (n= 9,521) who did or did not receive ALND, 
including those with T1–T2 disease and ≥ 3 positive lymph 
nodes upon SLNB [20]. With those studies, the recommenda-
tions were updated in 2011 the new National Comprehensive 
Cancer Network (NCCN) guidelines [21]. However, the 
adoption and implementation of NCCN recommendations 
have been slow and irregular, and there is still reluctance to 
adopt this as the new standard for patients undergoing BCS 
for early breast cancer. We have no data in this regard for 
Korean patients with breast cancer. As seen in Figure 4, the 
increase in the number of patients who underwent SLNB 
alone was similar to previous studies. The decrease in the total 
number of patients who underwent BCS after 2014 was 
thought to be owing to an increase in the number of mastec-
tomies and reconstructions. Despite decreasing BCS, the pro-
portion of SLNB alone increased. 
Among histologic subtypes, invasive lobular carcinoma is 
associated with DSS, but its incidence is rare in Korea, with 
only 3.5% in our study compared with 7.5% in the ACOSOG 
Z0011 trial. A study examining only invasive lobular breast 
carcinoma reported no effect of ALND on survival [22]. There 
are few studies on molecular subtypes, and one study revealed 
that ER or/and PR positive cases had significantly lower haz-
ard ratios than both negative cases [10]. However, there was 
no difference in DSS and OS among molecular subtypes in 
our study. Tumor size, total lymph node number, and positive 
lymph node number were significantly higher in the 
SLNB+ALND group than in the SLNB group; because this 
study was a retrospective study, it was not possible to ran-
domly assign the two groups. 
In our study, the number of lymph nodes harvested was 
very high in the group undergoing SLNB (5.90± 5.29). Based 
on the 7th edition of the American Joint Committee of Cancer 
(AJCC) staging criteria, six or more nodes removed consti-
tutes axillary clearance [23]. The number of sentinel lymph 
nodes reported in other studies have not always followed the 
accepted definition [9,24-26], as these studies have mostly col-
lected the data from the final pathology report. The disadvan-
tage of such an approach is that even though pathological as-
sessment might have been performed via SLNB during sur-
gery, lymph nodes may have been obtained from the sur-
rounding tissues, including some axillary lymph nodes. The 
total number of excised nodes was correlated with DSS in 
univariate analysis but not in multivariate analysis. The exact 
reason for this is difficult to determine due to the inherent 
characteristics of large databases. Additionally, the registry 
does not contain information about harvest methods for 
SLNB. The number of positive lymph nodes was a significant 
factor affecting OS in univariate and multivariate analysis; 
however, we only included patients with one or two positive 
nodes. We know that the number of positive nodes is a signifi-
cant risk factor in the prognosis of breast cancer, although all 
cases with one to three positive axillary lymph nodes are clas-
sified as pN1a, according to the AJCC staging manual [21]. 
Further studies in patients who have several lymph node me-
tastases are mandatory.
This study had some limitations. First, we cannot exclude 
selection bias owing to the retrospective nature of the study. 
The tumor stage, hormonal status, and prognosis were more 
favorable in the SLNB group, and more chemotherapy was 
administered in the ALND group; these factors could affect 
the statistical analysis results for the two groups. Secondly, 
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some data might be incomplete or incorrect, with some cases 
described as stages 3 and 4. Despite these limitations, we con-
sider the results of this study to be meaningful because they 
were obtained from a large number of patients of a single eth-
nicity, across multiple centers. Additionally, in patients meet-
ing the inclusion criteria, the surgical methods did not affect 
survival rates in the subgroups or in the overall group. Our 
study is a retrospective study, but our findings can serve as ba-
sic data for future matched cohorts; a prospective randomized 
study is necessary to further investigate the need for ALND in 
this population.
In conclusion, Korean patients with early breast cancer who 
had one or two positive axillary lymph nodes and received 
BCS plus SLNB showed no significant differences in DSS and 
OS, regardless of whether they underwent ALND. The num-
ber of patients who underwent SLNB alone for one or two 
positive lymph nodes increased from 2004 to 2014 in Korea. 
Although follow-up studies are required, our study indicates 
that we can consider omitting ALND when treating selected 
patients with early breast cancer.
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